Related Experiment Video
Updated: Jun 23, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
β-Carboline derivatives are potent against Acute Myeloid Leukemia in vitro and in vivo
Maura Lima Pereira Bueno1, Mary Ann Foglio1,2, Paula Baréa3
1Hematology and Transfusion Medicine Center, University of Campinas/Hemocentro-UNICAMP, Rua Carlos Chagas, 480 - Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP, CEP: 13083-878, Brazil.
Background:
β-carboline alkaloids exert a distinguished ability to impair cell growth and induce cell death in a variety of cancers and the evaluation of such new therapeutic candidates may denote new possibilities for leukemia treatment. In this present study, we screened 12 β-carboline derivatives containing different substituents at 1- and 3-positions of β-carboline nucleus for their antineoplastic activities in a panel of leukemia cell lines.
Methods:
The cytotoxic effects of the β-carboline derivatives were evaluated in different leukemia cell lines as well as reactive oxygen species (ROS) generation, autophagy, and important signaling pathways.
Results:
Treatment with the β-carboline derivatives resulted in a potent antineoplastic activity leading to a reduced cell viability that was associated with increased cell death in a concentration-dependent manner. Interestingly, the treatment of primary mononuclear cells isolated from the peripheral blood of healthy donors with the β-carboline derivatives showed a minor change in cell survival. The antineoplastic activity occurs by blocking ROS production causing consequent interruption of the PI3K/AKT and MAPK/ERK signaling and modulating autophagy processes. Notably, in vivo, AML burden was diminished in peripheral blood and bone marrow of a xenograft mouse model.
Conclusions:
Our results indicated that β-carboline derivatives have an on-target malignant cell-killing activity and may be promising candidates for treating leukemia cells by disrupting crucial events that promote leukemia expansion and chemotherapy resistance.
Insights
β-carboline derivatives show potent antineoplastic activity against leukemia cells by inducing cell death and blocking key signaling pathways. These compounds demonstrate promise as novel leukemia therapeutics with minimal impact on healthy cells.
Area of Science:
- Pharmacology
- Cancer Biology
- Medicinal Chemistry
Background:
- β-carboline alkaloids exhibit anti-cancer properties, including inhibiting cell growth and inducing cell death.
- This study investigates novel β-carboline derivatives as potential therapeutic agents for leukemia.
Purpose of the Study:
- To screen β-carboline derivatives for antineoplastic activity against leukemia cell lines.
- To elucidate the mechanisms underlying their cytotoxic effects.
Main Methods:
- Cytotoxicity assays were performed on various leukemia cell lines.
- Reactive oxygen species (ROS) generation, autophagy, and signaling pathways (PI3K/AKT, MAPK/ERK) were analyzed.
- In vivo efficacy was assessed using an acute myeloid leukemia (AML) xenograft mouse model.
Main Results:
- β-carboline derivatives demonstrated potent, concentration-dependent antineoplastic activity, reducing cell viability and increasing cell death.
- These compounds selectively targeted malignant cells, with minimal effects on healthy primary mononuclear cells.
- Mechanism involves blocking ROS production, interrupting PI3K/AKT and MAPK/ERK signaling, and modulating autophagy.
- In vivo studies showed a significant reduction in AML burden in mice.
Conclusions:
- β-carboline derivatives exhibit targeted killing of leukemia cells.
- These compounds disrupt critical pathways promoting leukemia expansion and chemotherapy resistance.
- β-carboline derivatives represent promising candidates for novel leukemia treatments.
Related Concept Videos
01:10Drugs that Destabilize Microtubules
02:34Inhibition of Cdk Activity